Vical (VICL) Commences Vaxfectin-Formulated, Bivalent, Therapeutic DNA Vaccine Phase 2 for HSV-2 : streetinsider

referring to streetinsider

Vical (VICL) Commences Vaxfectin-Formulated, Bivalent, Therapeutic DNA Vaccine Phase 2 for HSV-2

Vical (VICL) Commences Vaxfectin-Formulated, Bivalent, Therapeutic DNA Vaccine Phase 2 for HSV-2

Vical Incorporated (Nasdaq: VICL) announced today the initiation of a Phase 2 trial of the company's Vaxfectin™-formulated, bivalent, therapeutic DNA vaccine for herpes simplex virus type 2 (HSV-2) infection.The randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of the vaccine in approximately 225 healthy adults aged 18 to 50 years with symptomatic genital HSV-2 infection at up to 15 U.S. clinical sites."About one in six persons between the ages of 14 and 49 is infected with HSV-2.


in like manner genengnews

Novavax RSV F Vaccine Fails Phase III Trial

Novavax RSV F Vaccine Fails Phase III Trial

Novavax acknowledged that its respiratory syncytial virus (RSV) F-protein recombinant nanoparticle vaccine candidate failed a Phase III trial, sending the company's shares crashing by more than three-quarters in after-hours trading.RSV F Vaccine missed its primary and secondary efficacy endpoints in the Phase III Resolve trial, in which the vaccine was given to 11,856 adults aged 60 and older.The trial's primary objective was to show the RSV F Vaccine's efficacy in preventing moderate-severe RSV-associated lower respiratory tract disease (RSV msLRTD), defined by the presence of multiple lower respiratory tract symptoms.


moreover from kentuckypostnews

Vical Starts Phase 2 Trial on Vaccine For Genital Herpes (NASDAQ:VICL)

Vical Starts Phase 2 Trial on Vaccine For Genital Herpes (NASDAQ:VICL)

Vical Starts Phase 2 Trial on Vaccine For Genital Herpes (NASDAQ:VICL)Vical Inc. (NASDAQ:VICL) said pre-market Monday it has initiated a phase 2 trial that will evaluate its therapeutic DNA vaccine Vaxfectin for herpes simplex virus type 2 infection.The phase 2 trial will evaluate the vaccine in about 225 adults with symptomatic genital HSV-2 infection at up to 15 sites in the U.S, the company said."If we can demonstrate that this vaccine controls the frequency of HSV-2 recurrences, it may offer an exciting new treatment modality for physicians that would free patients from daily, antiviral drug usage," said lead investigator Anna Wald.